Gianfranco Pasut
TitleCited byYear
PEGylation, successful approach to drug delivery
FM Veronese, G Pasut
Drug discovery today 10 (21), 1451-1458, 2005
Polymer–drug conjugation, recent achievements and general strategies
G Pasut, FM Veronese
Progress in polymer science 32 (8-9), 933-961, 2007
State of the art in PEGylation: the great versatility achieved after forty years of research
G Pasut, FM Veronese
Journal of controlled release 161 (2), 461-472, 2012
PEG conjugates in clinical development or use as anticancer agents: an overview
G Pasut, FM Veronese
Advanced drug delivery reviews 61 (13), 1177-1188, 2009
PEG− doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity
FM Veronese, O Schiavon, G Pasut, R Mendichi, L Andersson, A Tsirk, ...
Bioconjugate chemistry 16 (4), 775-784, 2005
Polyoxazoline: chemistry, properties, and applications in drug delivery
TX Viegas, MD Bentley, JM Harris, Z Fang, K Yoon, B Dizman, R Weimer, ...
Bioconjugate chemistry 22 (5), 976-986, 2011
Synthesis and characterization of poly (2-ethyl 2-oxazoline)-conjugates with proteins and drugs: suitable alternatives to PEG-conjugates?
A Mero, G Pasut, L Dalla Via, MWM Fijten, US Schubert, R Hoogenboom, ...
Journal of Controlled Release 125 (2), 87-95, 2008
Antitumoral activity of PEG–gemcitabine prodrugs targeted by folic acid
G Pasut, F Canal, L Dalla Via, S Arpicco, FM Veronese, O Schiavon
Journal of Controlled Release 127 (3), 239-248, 2008
Protein, peptide and non-peptide drug PEGylation for therapeutic application
G Pasut, A Guiotto, FM Veronese
Expert Opinion on Therapeutic Patents 14 (6), 859-894, 2004
Anti-cancer PEG-enzymes: 30 years old, but still a current approach
G Pasut, M Sergi, FM Veronese
Advanced drug delivery reviews 60 (1), 69-78, 2008
PEGylation of proteins as tailored chemistry for optimized bioconjugates
G Pasut, FM Veronese
Polymer Therapeutics I, 95-134, 2006
Dendritic poly (ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms
C Clementi, K Miller, A Mero, R Satchi-Fainaro, G Pasut
Molecular pharmaceutics 8 (4), 1063-1072, 2011
PEG–Ara-C conjugates for controlled release
O Schiavon, G Pasut, S Moro, P Orsolini, A Guiotto, FM Veronese
European journal of medicinal chemistry 39 (2), 123-133, 2004
Site-specific pegylation of G-CSF by reversible denaturation
FM Veronese, A Mero, F Caboi, M Sergi, C Marongiu, G Pasut
Bioconjugate chemistry 18 (6), 1824-1830, 2007
Novel monodisperse PEG− dendrons as new tools for targeted drug delivery: synthesis, characterization and cellular uptake
M Berna, D Dalzoppo, G Pasut, M Manunta, L Izzo, AT Jones, R Duncan, ...
Biomacromolecules 7 (1), 146-153, 2006
PEGylation for improving the effectiveness of therapeutic biomolecules.
G Pasut, FM Veronese
Drugs of today (Barcelona, Spain: 1998) 45 (9), 687-695, 2009
Polyethylene glycol (PEG)-dendron phospholipids as innovative constructs for the preparation of super stealth liposomes for anticancer therapy
G Pasut, D Paolino, C Celia, A Mero, AS Joseph, J Wolfram, D Cosco, ...
Journal of controlled release 199, 106-113, 2015
Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol
G Pasut
BioDrugs 28 (1), 15-23, 2014
A new method to increase selectivity of transglutaminase mediated PEGylation of salmon calcitonin and human growth hormone
A Mero, M Schiavon, FM Veronese, G Pasut
Journal of controlled release 154 (1), 27-34, 2011
PEG-epirubicin conjugates with high drug loading
G Pasut, S Scaramuzza, O Schiavon, R Mendichi, FM Veronese
Journal of bioactive and compatible polymers 20 (3), 213-230, 2005
The system can't perform the operation now. Try again later.
Articles 1–20